These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 38383419

  • 1. First effectiveness data of lenvatinib and pembrolizumab as first-line therapy in advanced anaplastic thyroid cancer: a retrospective cohort study.
    Soll D, Bischoff P, Frisch A, Jensen M, Karadeniz Z, Mogl MT, Horst D, Penzkofer T, Spranger J, Keilholz U, Mai K.
    BMC Endocr Disord; 2024 Feb 22; 24(1):25. PubMed ID: 38383419
    [Abstract] [Full Text] [Related]

  • 2. Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma.
    Dierks C, Seufert J, Aumann K, Ruf J, Klein C, Kiefer S, Rassner M, Boerries M, Zielke A, la Rosee P, Meyer PT, Kroiss M, Weißenberger C, Schumacher T, Metzger P, Weiss H, Smaxwil C, Laubner K, Duyster J, von Bubnoff N, Miething C, Thomusch O.
    Thyroid; 2021 Jul 22; 31(7):1076-1085. PubMed ID: 33509020
    [Abstract] [Full Text] [Related]

  • 3. Combination of Lenvatinib and Pembrolizumab as Salvage Treatment for Paucicellular Variant of Anaplastic Thyroid Cancer: A Case Report.
    Luongo C, Porcelli T, Sessa F, De Stefano MA, Scavuzzo F, Damiano V, Klain M, Bellevicine C, Matano E, Troncone G, Schlumberger M, Salvatore D.
    Curr Oncol; 2021 Dec 16; 28(6):5401-5407. PubMed ID: 34940089
    [Abstract] [Full Text] [Related]

  • 4. Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer.
    Iñiguez-Ariza NM, Ryder MM, Hilger CR, Bible KC.
    Thyroid; 2017 Jul 16; 27(7):923-927. PubMed ID: 28471306
    [Abstract] [Full Text] [Related]

  • 5. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma.
    Iyer PC, Dadu R, Gule-Monroe M, Busaidy NL, Ferrarotto R, Habra MA, Zafereo M, Williams MD, Gunn GB, Grosu H, Skinner HD, Sturgis EM, Gross N, Cabanillas ME.
    J Immunother Cancer; 2018 Jul 11; 6(1):68. PubMed ID: 29996921
    [Abstract] [Full Text] [Related]

  • 6. Neoadjuvant treatment with lenvatinib and pembrolizumab in a BRAF V600E-mutated anaplastic thyroid cancer: a case report.
    Barbaro D, Forleo R, Profilo MA, Lapi P, Giani C, Torregrossa L, Macerola E, Materazzi G.
    Front Endocrinol (Lausanne); 2024 Jul 11; 15():1389294. PubMed ID: 39045273
    [Abstract] [Full Text] [Related]

  • 7. Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer.
    Gunda V, Gigliotti B, Ashry T, Ndishabandi D, McCarthy M, Zhou Z, Amin S, Lee KE, Stork T, Wirth L, Freeman GJ, Alessandrini A, Parangi S.
    Int J Cancer; 2019 May 01; 144(9):2266-2278. PubMed ID: 30515783
    [Abstract] [Full Text] [Related]

  • 8. Rationale Efficacy and Safety Evidence of Lenvatinib and Pembrolizumab Association in Anaplastic Thyroid Carcinoma.
    Boudin L, Morvan JB, Thariat J, Métivier D, Marcy PY, Delarbre D.
    Curr Oncol; 2022 Oct 14; 29(10):7718-7731. PubMed ID: 36290887
    [Abstract] [Full Text] [Related]

  • 9. Survival With Lenvatinib for the Treatment of Progressive Anaplastic Thyroid Cancer: A Single-Center, Retrospective Analysis.
    Kim SY, Kim SM, Kim JW, Lee IJ, Jeon TJ, Chang H, Kim BW, Lee YS, Chang HS, Park CS.
    Front Endocrinol (Lausanne); 2020 Oct 14; 11():599. PubMed ID: 32982983
    [Abstract] [Full Text] [Related]

  • 10. FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated Thyroid Cancer: Evaluation of the Preclinical Rationale.
    Adam P, Kircher S, Sbiera I, Koehler VF, Berg E, Knösel T, Sandner B, Fenske WK, Bläker H, Smaxwil C, Zielke A, Sipos B, Allelein S, Schott M, Dierks C, Spitzweg C, Fassnacht M, Kroiss M.
    Front Endocrinol (Lausanne); 2021 Oct 14; 12():712107. PubMed ID: 34475850
    [Abstract] [Full Text] [Related]

  • 11. Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma.
    Iyer PC, Dadu R, Ferrarotto R, Busaidy NL, Habra MA, Zafereo M, Gross N, Hess KR, Gule-Monroe M, Williams MD, Cabanillas ME.
    Thyroid; 2018 Jan 14; 28(1):79-87. PubMed ID: 29161986
    [Abstract] [Full Text] [Related]

  • 12. Real-world experience of lenvatinib in patients with advanced anaplastic thyroid cancer.
    Kim M, Ahn J, Song DE, Yoon JH, Kang HC, Lim DJ, Kim WG, Kim TY, Kim WB, Shong YK, Jeon MJ, Kim BH.
    Endocrine; 2021 Feb 14; 71(2):427-433. PubMed ID: 32729092
    [Abstract] [Full Text] [Related]

  • 13. Pharmacological effects of vinorelbine in combination with lenvatinib in anaplastic thyroid cancer.
    Di Desidero T, Orlandi P, Gentile D, Banchi M, Alì G, Kusmic C, Armanetti P, Cayme GJ, Menichetti L, Fontanini G, Francia G, Bocci G.
    Pharmacol Res; 2020 Aug 14; 158():104920. PubMed ID: 32461187
    [Abstract] [Full Text] [Related]

  • 14. Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer.
    Wirth LJ, Brose MS, Sherman EJ, Licitra L, Schlumberger M, Sherman SI, Bible KC, Robinson B, Rodien P, Godbert Y, De La Fouchardiere C, Newbold K, Nutting C, Misir S, Xie R, Almonte A, Ye W, Cabanillas ME.
    J Clin Oncol; 2021 Jul 20; 39(21):2359-2366. PubMed ID: 33961488
    [Abstract] [Full Text] [Related]

  • 15. Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE).
    Higashiyama T, Sugino K, Hara H, Ito KI, Nakashima N, Onoda N, Tori M, Katoh H, Kiyota N, Ota I, Suganuma N, Hibi Y, Nemoto T, Takahashi S, Yane K, Ioji T, Kojima S, Kaneda H, Sugitani I, Tahara M.
    Eur J Cancer; 2022 Sep 20; 173():210-218. PubMed ID: 35932627
    [Abstract] [Full Text] [Related]

  • 16. Safety and Effectiveness of Lenvatinib in 594 Patients with Unresectable Thyroid Cancer in an All-Case Post-Marketing Observational Study in Japan.
    Takahashi S, Tahara M, Ito K, Tori M, Kiyota N, Yoshida K, Sakata Y, Yoshida A.
    Adv Ther; 2020 Sep 20; 37(9):3850-3862. PubMed ID: 32676927
    [Abstract] [Full Text] [Related]

  • 17. Multimodal treatments and outcomes for anaplastic thyroid cancer before and after tyrosine kinase inhibitor therapy: a real-world experience.
    Park J, Jung HA, Shim JH, Park WY, Kim TH, Lee SH, Kim SW, Ahn MJ, Park K, Chung JH.
    Eur J Endocrinol; 2021 May 06; 184(6):837-845. PubMed ID: 33852431
    [Abstract] [Full Text] [Related]

  • 18. Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers.
    French JD, Haugen BR, Worden FP, Bowles DW, Gianoukakis AG, Konda B, Dadu R, Sherman EJ, McCue S, Foster NR, Nikiforov YE, Farias TDJ, Norman PJ, Wirth LJ.
    Clin Cancer Res; 2024 Sep 03; 30(17):3757-3767. PubMed ID: 38922338
    [Abstract] [Full Text] [Related]

  • 19. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
    Ito Y, Onoda N, Ito KI, Sugitani I, Takahashi S, Yamaguchi I, Kabu K, Tsukada K.
    Thyroid; 2017 Sep 03; 27(9):1142-1148. PubMed ID: 28635560
    [Abstract] [Full Text] [Related]

  • 20. A long survival patient of anaplastic thyroid carcinoma treated with lenvatinib.
    Hamamoto T, Kono T, Taruya T, Ishino T, Ueda T, Takeno S.
    Auris Nasus Larynx; 2022 Jun 03; 49(3):515-519. PubMed ID: 33109426
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.